# FDA Guidance for Industry: Biologics Compliance Overview

## Introduction to FDA Guidance for Biologics

### What Are FDA Guidance Documents?

FDA guidance documents represent the agency's current thinking on a regulatory topic. They are prepared by FDA staff and reflect the agency's interpretation of statutes and regulations. Guidance documents are not legally binding on either the agency or the regulated industry; rather, they describe a recommended approach that, if followed, generally results in a submission that FDA finds acceptable. When a manufacturer deviates from a guidance, the deviation itself is not a violation, but the manufacturer must be prepared to justify the alternative approach with appropriate data.

For biologics, guidance documents cover the entire product lifecycle, from preclinical development through post-marketing surveillance. The FDA issues these documents as draft or final versions. Draft guidances are available for comment, and the agency considers public input before finalizing. However, even draft guidances signal the agency's current thinking and are frequently used by sponsors to design development programs. A comprehensive listing of relevant documents is maintained on the FDA website, and the [FDA Guidance Documents Biologics](/knowledge/molecular-biology/fda-guidance-documents-biologics) resource provides a structured overview of the most frequently cited documents in this space.

### Scope of Biologics Regulation

Biologics encompass a broad category of products, including therapeutic proteins, monoclonal antibodies, vaccines, gene therapies, cellular therapies, blood products, and allergenic extracts. These products are distinguished from small-molecule drugs by their size, complexity, and the fact that they are typically produced in living systems. The inherent variability of biological manufacturing means that the regulatory framework emphasizes process control, product characterization, and consistency of manufacture to a degree not seen with conventional pharmaceuticals.

The regulatory scope extends beyond the product itself to include the facilities where it is manufactured, the equipment used, the raw materials, and the analytical methods employed for release and stability testing. This holistic approach reflects the reality that for biologics, the process is the product—a principle that underpins the FDA's expectations for chemistry, manufacturing, and controls (CMC) data.

## Regulatory Framework for Biologics

### Key Statutes and Regulations

The primary statutory authority for biologics regulation is the Public Health Service (PHS) Act, specifically Section 351 (42 U.S.C. § 262). This section requires that a biologics license application (BLA) be approved before a biological product may be introduced into interstate commerce. The PHS Act establishes two pathways for licensure: Section 351(a) for originator biologics and Section 351(k) for biosimilars and interchangeable products.

The Federal Food, Drug, and Cosmetic (FD&C) Act also applies to biologics, particularly with respect to labeling, adverse event reporting, and good manufacturing practices. The FD&C Act's provisions on new drug applications (NDAs) do not directly govern biologics, but the act's general provisions on adulteration, misbranding, and registration apply. The implementing regulations for biologics are found primarily in Title 21 of the Code of Federal Regulations (CFR), Parts 600–680, which cover licensing, establishment standards, and product standards. Additional relevant regulations include 21 CFR Part 210 and 211 for current good manufacturing practice (CGMP), and 21 CFR Part 312 for investigational new drug (IND) applications.

### CBER vs. CDER Responsibilities

The Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) share oversight of biological products, with the division of responsibility determined by product category. CBER regulates vaccines, blood components and derivatives, allergenic extracts, cellular and gene therapies, and tissue-based products. CDER regulates therapeutic proteins, including monoclonal antibodies, cytokines, growth factors, enzymes, and immunomodulators, as well as biosimilars of these products.

This division was formalized in 2003 when therapeutic biological products were transferred from CBER to CDER. The rationale was that these products more closely resemble drugs in their development and clinical evaluation. However, CBER retains authority over products where the mechanism of action involves the immune system in a way that is not primarily therapeutic—for example, vaccines that prevent infectious disease. For sponsors, the first regulatory question is often simply: which center has jurisdiction over my product? The answer determines the review division, the format of meetings, and the specific guidance documents that apply. The [FDA Regulations for Biologics](/knowledge/molecular-biology/fda-regulations-for-biologics) resource provides a detailed breakdown of the regulatory text governing these assignments.

## Key [FDA Guidance Documents for Biologics](/knowledge/molecular-biology/fda-guidance-documents-biologics) Development

### Biosimilar Guidance

The biosimilar pathway, established by the Biologics Price Competition and Innovation Act of 2009, has generated a substantial body of FDA guidance. The foundational document is "Scientific Considerations in Demonstrating Biosimilarity to a Reference Product," which outlines the stepwise approach to demonstrating that a proposed biosimilar is highly similar to the reference product notwithstanding minor differences in clinically inactive components, and that there are no clinically meaningful differences in safety, purity, and potency.

A companion guidance, "Quality Considerations in Demonstrating Biosimilarity," addresses CMC expectations, emphasizing the need for extensive analytical characterization to establish the fingerprint-like similarity between the proposed product and the reference product. This includes state-of-the-art analytical methods such as peptide mapping with mass spectrometry, circular dichroism for higher-order structure, and surface plasmon resonance for binding kinetics. The guidance also discusses the use of functional assays, which should be selected based on the mechanism of action of the reference product.

The "Clinical Pharmacology Data to Support a Demonstration of Biosimilarity" guidance describes the role of pharmacokinetic and pharmacodynamic studies, including the use of a sensitive population and the selection of appropriate study endpoints. Sponsors should also consult the guidance on "Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors," which outlines the specific meeting types available for biosimilar development, including the Biosimilar Initial Advisory (BIA) meeting.

### CMC Guidance

For CMC, the most frequently cited guidance is "Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process," which was adopted from the International Council for Harmonisation (ICH). This guidance describes the approach to demonstrating that a manufacturing process change does not adversely affect product quality, safety, or efficacy. The principles of comparability are central to lifecycle management of biologics, as process changes are inevitable over the product's lifetime.

Another critical document is "Q11 Development and Manufacture of Drug Substances," which describes the approach to process development, including the establishment of design space and the use of quality by design (QbD) principles. For biologics, Q11 emphasizes the importance of understanding the relationship between process parameters and critical quality attributes (CQAs). The guidance also discusses the concept of the control strategy, which is the planned set of controls, derived from current product and process understanding, that ensures process performance and product quality.

The "Container Closure Systems for Packaging Human Drugs and Biologics" guidance addresses the requirements for the packaging system, including extractables and leachables studies, which are particularly important for biologics due to the potential for interaction between the product and the container. For products stored in prefilled syringes, the guidance on "Technical Considerations for Pen, Jet, and Related Injectors" is also relevant.

### Clinical Trial Guidance

Clinical development of biologics follows the same general framework as for drugs, but with specific considerations. The guidance "Expedited Programs for Serious Conditions – Drugs and Biologics" describes the four expedited programs available: fast track, breakthrough therapy, accelerated approval, and priority review. Sponsors should consider whether their product qualifies for any of these programs early in development, as the designation can significantly shorten the development timeline.

The "Immunogenicity Assessment for Therapeutic Protein Products" guidance is unique to biologics and addresses the evaluation of anti-drug antibodies (ADAs). This guidance describes a risk-based approach to immunogenicity testing, with the extent of testing dependent on the product's immunogenicity risk category. The guidance recommends a tiered approach to ADA detection: screening, confirmation, and characterization (titer, neutralizing capacity, and isotype). Assay development should follow the recommendations in the companion guidance "Immunogenicity Testing of Therapeutic Protein Products – Developing and Validating Assays for Anti-Drug Antibody Detection."

For gene therapies, the guidance "Chemistry, Manufacturing, and Control (CMC) Information for Human [Gene Therapy](/blog/guides/gene-therapy) Investigational New Drug Applications (INDs)" provides product-specific recommendations. This guidance addresses vector characterization, including the determination of vector copy number, integration site analysis, and the assessment of replication-competent virus. For cell therapies, the guidance "Potency Tests for Cellular and [Gene Therapy](/blog/guides/gene-therapy) Products" describes the expectations for potency assay development, which should measure the product's biological activity relevant to its intended clinical effect.

## Chemistry, Manufacturing, and Controls (CMC) Requirements

### [Process Validation](/knowledge/molecular-biology/process-validation)

Process validation for biologics is governed by the FDA guidance "Process Validation: General Principles and Practices," which describes a three-stage approach: process design, process qualification, and continued process verification. For biologics, process design begins during development, where the relationship between process parameters and product quality is established. This includes the use of design of experiments (DoE) to identify critical process parameters (CPPs) and their acceptable ranges.

Process qualification involves demonstrating that the process, as designed, is capable of reproducibly producing a product meeting its predetermined quality attributes. For biologics, this typically involves the manufacture of three consecutive commercial-scale batches that meet all release specifications. The qualification batches must also demonstrate stability, as the data from these batches form the basis of the initial shelf-life assignment.

Continued process verification involves ongoing monitoring of the process during commercial manufacture to ensure that it remains in a state of control. This includes statistical process control, trend analysis of CQAs, and periodic review of process performance. For biologics, the monitoring program should include in-process parameters such as cell viability, culture duration, and harvest titer, as well as product quality attributes such as aggregation, fragmentation, and glycosylation profiles.

### Product Characterization

Product characterization is the foundation of the CMC package for a biologic. The goal is to establish a comprehensive understanding of the product's structure, biological activity, and heterogeneity. For a monoclonal antibody, this includes primary structure confirmation by peptide mapping with liquid chromatography-tandem mass spectrometry (LC-MS/MS), which should achieve at least 95% sequence coverage. Disulfide bond mapping is performed to confirm correct pairing of cysteine residues. Higher-order structure is assessed by circular dichroism (far-UV for secondary structure, near-UV for tertiary structure) and by differential scanning calorimetry to determine thermal stability.

Glycosylation analysis is critical for many biologics, as glycan profiles can affect efficacy, half-life, and immunogenicity. The typical approach involves release of N-glycans with PNGase F, followed by labeling with 2-aminobenzamide (2-AB) and analysis by hydrophilic interaction liquid chromatography (HILIC) with fluorescence detection. The relative abundance of major glycan species—such as G0F, G1F, and G2F—should be quantified and controlled. Sialic acid content is determined by release with neuraminidase and analysis by high-performance anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD).

Charge variants are assessed by ion-exchange chromatography or capillary isoelectric focusing (cIEF). The distribution of acidic and basic variants should be characterized, as these can arise from deamidation, oxidation, or C-terminal lysine processing. Size variants are analyzed by size-exclusion chromatography (SEC) to quantify aggregates and fragments, with typical specifications allowing no more than 5% high-molecular-weight species for a monoclonal antibody. Subvisible particles are measured by light obscuration and, for particles in the 2–10 µm range, by micro-flow imaging.

### Stability Testing

Stability testing for biologics follows the ICH Q5C guidance, which addresses the specific considerations for biotechnology products. The primary purpose is to establish a shelf life and storage conditions that maintain product quality throughout the labeled period. For most biologics, the recommended storage condition is 2–8°C, protected from light. Some products require frozen storage at -20°C or -70°C, and the stability program must include data supporting the freeze-thaw stability if the product is intended to be frozen.

The stability protocol should include a full panel of product quality assays, including potency, purity, and physicochemical characterization. For a monoclonal antibody, the typical stability-indicating assays include SEC for aggregation, ion-exchange chromatography for charge variants, and a cell-based bioassay for potency. The frequency of testing is typically every 3 months for the first year, every 6 months for the second year, and annually thereafter. For products stored at 2–8°C, the program should extend to at least 12 months beyond the proposed shelf life to support the initial submission.

Accelerated and stress stability studies are also required. Accelerated studies at 25°C and 37°C for 1–3 months provide information on the degradation pathways and help establish the product's sensitivity to temperature excursions. Stress studies, including exposure to light, oxidation, and repeated freeze-thaw cycles, identify the product's degradation profile and inform the development of the control strategy. The data from these studies are used to set specifications for product quality attributes that are stability-indicating.

## Pre-IND and IND Submissions

### Pre-IND Meeting Process

The pre-IND meeting is an opportunity for sponsors to obtain FDA feedback on their development plan before submitting an IND. This meeting is particularly valuable for biologics, where the CMC requirements are complex and the agency's expectations can be product-specific. The meeting request should be submitted to the appropriate review division, and the request should include a brief summary of the product, the proposed indication, and the specific questions to be discussed.

The pre-IND meeting package should be submitted at least 30 days before the requested meeting date. The package typically includes a summary of the product's mechanism of action, the proposed manufacturing process, the analytical methods for product characterization, and the proposed clinical development plan. For a biologic, the CMC section should address the cell line or expression system, the upstream and downstream process, the purification scheme, and the proposed specifications. The package should also include a summary of the nonclinical pharmacology and toxicology data.

The FDA will provide written responses to the questions in the meeting package, and these responses form the basis of the meeting discussion. The meeting itself is typically 60–90 minutes and is attended by the sponsor's regulatory, CMC, and clinical teams, along with the FDA review team. The outcome of the meeting is documented in meeting minutes, which are prepared by the FDA and issued within 30 days. These minutes are a critical regulatory document, as they represent the agency's positions on the topics discussed.

### IND Content and Format

The IND submission for a biologic follows the format described in 21 CFR Part 312.23, which requires the submission of Form FDA 1571, the initial IND submission, and the protocol for the proposed clinical study. The CMC section, which is Section 3.2.S of the CTD format, must include a description of the drug substance, including its physical, chemical, and biological characteristics. For a biologic, this includes the [amino acid sequence](/blog/guides/amino-acid-sequence), the predicted molecular weight, the glycosylation profile, and the biological activity.

The manufacturing section must describe the source of the biological material, including the cell line history, the expression construct, and the cell banking system. The upstream process description should include the culture medium composition, the fermentation or cell culture conditions (temperature, pH, dissolved oxygen), and the scale of manufacture. The downstream process description should include the purification steps, with the rationale for each step and the expected removal of impurities, including host cell proteins, host cell DNA, and process-related impurities.

The analytical methods section should describe the release assays, including the reference standard and the specifications. For a biologic, the specifications should include appearance, pH, protein concentration, purity (by SEC and CE-SDS), potency, and identity. The stability data should include the results of the stability studies conducted to date, with a commitment to continue the studies. The IND should also include the environmental assessment or a claim for categorical exclusion.

## BLA Submission and Review Process

### BLA Components

The Biologics License Application (BLA) is the submission that requests permission to introduce a biologic into interstate commerce. The BLA is submitted in electronic Common Technical Document (eCTD) format and includes the full CMC dataset, the nonclinical data, and the clinical data. The CMC section must demonstrate that the product is safe, pure, and potent, and that the manufacturing process is consistent and well-controlled.

The BLA must include a full description of the manufacturing facility, including the layout, the equipment, and the utilities. The facility description must demonstrate compliance with CGMP, and the application must include the results of the FDA's pre-license inspection (PLI). The BLA must also include the establishment information, including the license number for the facility, and the environmental assessment.

The clinical section must include the results of all clinical studies conducted to support the indication, including the pharmacokinetic, pharmacodynamic, efficacy, and safety data. The labeling must be submitted in the Physician Labeling Rule (PLR) format, and the application must include the Medication Guide, if required. The BLA must also include the risk evaluation and mitigation strategy (REMS), if applicable, and the post-marketing commitments and requirements.

### FDA Review Process and Timelines

The FDA review of a BLA is governed by the Prescription Drug User Fee Act (PDUFA) timelines. For a standard review, the FDA has 10 months from the date of receipt to complete its review. For a priority review, the timeline is 6 months. The review clock begins when the FDA determines that the application is complete and acceptable for filing, which typically occurs within 60 days of receipt.

The review process involves a multidisciplinary team, including chemists, pharmacologists, clinicians, and statisticians. The CMC review focuses on the manufacturing process, the product characterization, and the stability data. The clinical review evaluates the efficacy and safety data, and the statistical review assesses the adequacy of the statistical analyses. The review team may issue information requests (IRs) during the review, and the sponsor must respond within the specified timeframe, typically 30 days.

At the end of the review, the FDA may issue a complete response letter (CRL) if the application is not approvable, or an approval letter if the application meets the requirements. The approval letter includes the approved labeling, the post-marketing requirements (PMRs), and the post-marketing commitments (PMCs). The FDA may also require a REMS to ensure that the benefits of the product outweigh the risks. The [Biologics License Application FDA](/knowledge/molecular-biology/biologics-license-application-fda) resource provides a detailed walkthrough of the BLA submission and review process, including the specific content requirements for each module of the eCTD.

## Post-Approval Considerations and Pharmacovigilance

### Post-Approval Changes

Once a biologic is approved, the manufacturer must maintain the product's quality and safety throughout its commercial life. Changes to the manufacturing process, the facility, or the product itself are governed by the FDA's post-approval change regulations, which are described in 21 CFR 601.12. The changes are categorized into three tiers based on the potential impact on product quality: major changes (Prior Approval Supplement, PAS), moderate changes (Changes Being Effected in 30 Days, CBE-30), and minor changes (Annual Report).

A major change is one that has a substantial potential to affect the product's identity, strength, quality, purity, or potency. Examples include a change in the cell line, a change in the purification process, or a change in the manufacturing facility. These changes require FDA approval before implementation, and the supplement must include the data demonstrating that the change does not adversely affect the product. The [FDA Post Approval Changes Guidance Biologics](/knowledge/molecular-biology/fda-post-approval-changes-guidance-biologics) resource provides a comprehensive overview of the regulatory requirements for each change category.

A moderate change is one that has a moderate potential to affect the product, and the supplement must be submitted at least 30 days before the change is implemented. Examples include a change in the analytical method or a change in the specification. A minor change is one that has minimal potential to affect the product, and these changes are reported in the annual report. Examples include minor equipment changes or administrative changes.

### Pharmacovigilance and Risk Evaluation

Post-marketing pharmacovigilance for biologics is governed by the same regulations that apply to drugs, including the adverse event reporting requirements in 21 CFR Part 314.80. Manufacturers must submit individual case safety reports (ICSRs) for serious and unexpected adverse events within 15 days of receipt, and for non-serious adverse events in periodic safety update reports (PSURs). The PSUR is submitted every 6 months for the first 2 years after approval, and annually for the next 2 years.

For biologics, immunogenicity is a particular concern, and the post-marketing surveillance program should include a strategy for detecting and evaluating anti-drug antibodies. The manufacturer should also monitor for adverse events that are specific to the product's mechanism of action, such as cytokine release syndrome for T-cell engagers or infusion-related reactions for monoclonal antibodies.

The risk evaluation and mitigation strategy (REMS) is required when the FDA determines that the product's benefits outweigh its risks, but that a risk management plan is necessary to ensure that the benefits are realized. The REMS may include elements to assure safe use (ETASU), such as prescriber certification, patient registries, or restricted distribution. The manufacturer must conduct assessments of the REMS at specified intervals to evaluate whether the program is meeting its goals.

## Common Pitfalls and Practical Tips for Compliance

### Common Pitfalls

One of the most frequent pitfalls in [biologics development](/knowledge/molecular-biology/biologics-development) is inadequate product characterization. Sponsors sometimes submit a BLA with insufficient data on the product's heterogeneity, particularly with respect to glycosylation and charge variants. The FDA expects a comprehensive analytical package that demonstrates a thorough understanding of the product's structure and its relationship to biological activity. Sponsors should invest in state-of-the-art analytical methods early in development and use them consistently throughout the product lifecycle.

Another common pitfall is the failure to establish a robust control strategy. The control strategy should link the CQAs to the CPPs and should include appropriate specifications for release and stability. Sponsors sometimes set specifications that are too broad, which can result in the release of product that is not sufficiently consistent. Conversely, specifications that are too narrow can lead to batch failures and supply disruptions. The specifications should be based on the product's clinical experience and should be justified with data.

A third pitfall is the underestimation of the importance of the pre-IND meeting. Sponsors who skip this meeting or submit an inadequate meeting package often encounter significant delays later in development. The pre-IND meeting is an opportunity to align with the FDA on the development plan, and the feedback received can save substantial time and resources. Sponsors should prepare a comprehensive meeting package that addresses the key CMC, nonclinical, and clinical questions.

### Best Practices for Regulatory Success

The most successful sponsors treat regulatory strategy as an integral part of product development, not as an afterthought. This means engaging with the FDA early and often, using the guidance documents as a roadmap, and building a regulatory team with deep experience in biologics. The [Biologics Regulatory Affairs Course](/knowledge/molecular-biology/biologics-regulatory-affairs-course) provides a structured curriculum for building this expertise.

Sponsors should also invest in quality by design (QbD) principles, which can reduce the burden of post-approval changes and provide flexibility in the manufacturing process. The use of design space, where the relationship between process parameters and CQAs is understood, can allow for adjustments within the design space without regulatory submission. This approach requires a significant investment in process characterization, but the long-term benefits are substantial.

Finally, sponsors should maintain a close relationship with their contract manufacturing organizations (CMOs) and ensure that the CMO's quality systems are aligned with FDA expectations. The FDA's inspection of the manufacturing facility is a critical step in the BLA review, and the sponsor is ultimately responsible for the quality of the product, regardless of where it is manufactured. The [FDA Approval Process for Biologics](/knowledge/molecular-biology/fda-approval-process-for-biologics) resource provides a step-by-step overview of the regulatory pathway, including the inspection process and the common deficiencies identified during inspections.

## Frequently Asked Questions

### What is the FDA guidance for industry biologics?

The FDA guidance for industry biologics refers to the collection of guidance documents issued by the FDA that describe the agency's current thinking on the development, manufacturing, and regulation of biological products. These documents cover topics such as CMC requirements, clinical trial design, biosimilar development, immunogenicity assessment, and post-approval changes. They are not legally binding, but they represent the FDA's recommended approach and are used by sponsors to design their development programs.

### Are FDA guidance documents legally binding?

No, FDA guidance documents are not legally binding. They describe the agency's current thinking on a topic and represent a recommended approach. However, the FDA will generally expect sponsors to follow the recommendations in a guidance, and deviations must be justified with appropriate data. The underlying statutes and regulations are legally binding, and guidance documents are the FDA's interpretation of those requirements.

### What is the difference between a BLA and an NDA?

A Biologics License Application (BLA) is the submission required for approval of a biological product under the PHS Act, while a New Drug Application (NDA) is the submission required for approval of a small-molecule drug under the FD&C Act. The BLA is governed by 21 CFR Part 601, while the NDA is governed by 21 CFR Part 314. The content requirements are similar, but the BLA places greater emphasis on the manufacturing process and product characterization, reflecting the inherent variability of biological products.

### What is a 351(k) application?

A 351(k) application is a BLA submitted under Section 351(k) of the PHS Act for a biosimilar or interchangeable biological product. This pathway allows for the approval of a product that is highly similar to an already-approved reference product, notwithstanding minor differences in clinically inactive components. The 351(k) application relies on the FDA's finding that the reference product is safe and effective, and the sponsor must demonstrate biosimilarity through analytical, nonclinical, and clinical studies.

### How do I request a pre-IND meeting with the FDA?

To request a pre-IND meeting, submit a written request to the appropriate review division. The request should include a brief summary of the product, the proposed indication, and the specific questions to be discussed. The FDA will respond within 21 days, and if the meeting is granted, the sponsor must submit a meeting package at least 30 days before the meeting date. The meeting package should include a summary of the product's development plan, including the CMC, nonclinical, and clinical sections.

### What are the key CMC requirements for biologics?

The key CMC requirements for biologics include a comprehensive description of the manufacturing process, including the cell line, the upstream and downstream process, and the purification scheme. The product must be fully characterized, including primary structure, higher-order structure, glycosylation, charge variants, and size variants. The application must include specifications for release and stability, and the stability data must support the proposed shelf life. The manufacturing facility must comply with CGMP, and the process must be validated.

### What are common pitfalls in [biologics development](/knowledge/molecular-biology/biologics-development)?

Common pitfalls in biologics development include inadequate product characterization, insufficient attention to the control strategy, and underestimation of the importance of the pre-IND meeting. Sponsors also frequently struggle with the complexity of the manufacturing process, particularly with respect to scalability and consistency. A lack of experience with the regulatory requirements for biologics can lead to delays and increased costs, making it essential to build a regulatory team with deep expertise in this area.

## Key Takeaways

- FDA guidance documents are not legally binding but represent the agency's current thinking; following them reduces the risk of regulatory delays.
- The PHS Act Section 351 provides the statutory basis for biologics regulation, with 351(a) for originator products and 351(k) for biosimilars.
- CBER and CDER share oversight of biologics, with the division of responsibility determined by product category.
- Product characterization is the foundation of the CMC package, requiring state-of-the-art analytical methods to establish a comprehensive understanding of the product's structure and heterogeneity.
- The pre-IND meeting is a critical opportunity to align with the FDA on the development plan and should not be skipped.
- Post-approval changes are governed by 21 CFR 601.12, with changes categorized as major, moderate, or minor based on their potential impact on product quality.
- Common pitfalls include inadequate characterization, weak control strategies, and insufficient engagement with the FDA; these can be avoided by investing in regulatory expertise and quality by design principles.

## Further Reading

- de Vlieger JSB et al. *Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: "Drug Products, Including Biological Products, that Contain Nanomaterials"*. The AAPS journal. 2019. [PubMed 30997588](https://doi.org/10.1208/s12248-019-0329-7)
- *Draft guidance for industry on developing medical imaging drugs and biologics; availability--FDA. Availability of guidance*. Federal register. 1998. [PubMed 10185833](https://pubmed.ncbi.nlm.nih.gov/10185833/)
- *"Guidance for Industry: For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Blood and Blood Components Intended for Transfusion or for Further Manufacture and for the Completion of the Form FDA 356h, 'Application to Market a New Drug, Biologic or an Antibiotic Drug for Human Use;'" availability. Food and Drug Administration, HHS. Notice*. Federal register. 1999. [PubMed 10558535](https://pubmed.ncbi.nlm.nih.gov/10558535/)
- *Draft guidance for industry; exports and imports under the FDA Export Reform and Enhancement Act of 1996--FDA. Notice*. Federal register. 1998. [PubMed 10180275](https://pubmed.ncbi.nlm.nih.gov/10180275/)
- U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services [FDA Center for Biologics](/knowledge/molecular-biology/fda-center-for-biologics) Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. *Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance*. Health and quality of life outcomes. 2006. [PubMed 17034633](https://doi.org/10.1186/1477-7525-4-79)
- Zamiri C et al. *Best Practices for Microbial Challenge In-Use Studies to Evaluate the Microbial Growth Potential of Parenteral Biological Products; Industry and Regulatory Considerations*. PDA journal of pharmaceutical science and technology. 2024. [PubMed 37848203](https://doi.org/10.5731/pdajpst.2022.012806)

## Related Clinical & Scientific Guides

* [MAPK Pathway: Mechanism, Function, and Clinical Relevance](/knowledge/molecular-biology/mapk-pathway)
* [Mammalian Cell Culture Bioreactors: A Practical Guide](/knowledge/molecular-biology/mammalian-cell-culture-bioreactor)
* [Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks](/knowledge/molecular-biology/nucleotide-formation)